Startseite EGFR and EGFR ligands in serum in healthy women; reference intervals and age dependency
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

EGFR and EGFR ligands in serum in healthy women; reference intervals and age dependency

  • Ina Mathilde Kjær ORCID logo EMAIL logo , Dorte Aalund Olsen , Anne Alnor ORCID logo , Ivan Brandslund ORCID logo , Troels Bechmann ORCID logo und Jonna Skov Madsen ORCID logo
Veröffentlicht/Copyright: 16. Juli 2019
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Background

The epidermal growth factor receptor (EGFR) system is involved in cancer pathogenesis and serves as an important target for multiple cancer treatments. EGFR and its ligands epidermal growth factor (EGF), heparin-binding epidermal growth factor (HB-EGF), betacellulin (BTC), amphiregulin (AREG) and transforming growth factor α (TGF-α) have potential applications as prognostic or predictive serological biomarkers in cancer. The aim was to establish EGFR and EGFR ligand reference intervals in healthy women.

Methods

EGFR and EGFR ligands were measured in serum from 419 healthy women aged 26–78 years. The need for age partitioned reference intervals was evaluated using Lahti’s method. EGFR and EGF were analyzed using ELISA assays, whereas HB-EGF, BTC, AREG and TGF-α were analyzed using the highly sensitive automated single molecule array (Simoa) enabling detection below the lower reference limit for all six biomarkers.

Results

Reference intervals for EGFR and the EGFR ligands were determined as the 2.5th and 97.5th percentiles. All six biomarkers were detectable in all serum samples. For EGFR, EGF, HB-EGF and TGF-α, reference intervals were established for women <55 years and for women >55 years, whilst common reference intervals were established for AREG and BTC including women aged 26–78 years.

Conclusions

Age specific reference intervals were determined for EGFR, EGF, HB-EGF, BTC, AREG and TGF-α.


Corresponding author: Ina Mathilde Kjær MD, Department of Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern Denmark, Beriderbakken 4, 7100 Vejle, Denmark; and Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark

Acknowledgments

Oluf Borbye Pedersen, Torben Hansen, and Cramer Christensen are acknowledged for providing the blood samples from Vejle Diabetes Biobank to the study. Assistant Jannie Møller and laboratory technicians Camilla Davidsen and Sara Egsgaard are acknowledged for their excellent contributions to this work. OPEN, Patient data Explorative Network, Odense University Hospital, Odense, Denmark are acknowledged for the collaboration on data management.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: The study was supported by grants from the Research Committee, Lillebaelt Hospital, Vejle, Denmark, the Region of Southern Denmark, and from the University of Southern Denmark.

  3. Employment or leadership: Ivan Brandslund is a member of the editorial board of Clinical Chemistry and Laboratory Medicine.

  4. Honorarium: None declared.

  5. Competing interests: No funding organization played a role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014;79:34–74.10.1016/j.phrs.2013.11.002Suche in Google Scholar

2. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, FelipE, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239–46.10.1016/S1470-2045(11)70393-XSuche in Google Scholar

3. Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015;33:692–700.10.1200/JCO.2014.59.4812Suche in Google Scholar

4. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, RomieuCG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533–43.10.1007/s10549-007-9885-0Suche in Google Scholar

5. Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016;17:367–77.10.1016/S1470-2045(15)00551-3Suche in Google Scholar

6. Roskoski R Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res 2019;139:395–411.10.1016/j.phrs.2018.11.014Suche in Google Scholar PubMed

7. Addison CL, Ding K, Zhao H, Le Maitre A, Goss GD, Seymour L, et al. Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. J Clin Oncol 2010;28:5247–56.10.1200/JCO.2010.31.0805Suche in Google Scholar PubMed

8. Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Hayama S, et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005;65:9176–84.10.1158/0008-5472.CAN-05-1556Suche in Google Scholar PubMed

9. Gregorc V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, et al. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004;10(18 Pt 1):6006–12.10.1158/1078-0432.CCR-03-0770Suche in Google Scholar PubMed

10. Tas F, Karabulut S, Serilmez M, Ciftci R, Duranyildiz D. Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer. Cancer Chemother Pharmacol 2014;73:631–7.10.1007/s00280-014-2396-xSuche in Google Scholar PubMed

11. Izuchi D, Fukagawa S, Yotsumoto F, Shigekawa K, YoshikawaK, Hirakawa T, et al. Association of serum HB-EGF value and response to chemotherapy in patients with recurrent ovarian cancer. Anticancer Res 2018;38:4347–51.10.21873/anticanres.12735Suche in Google Scholar PubMed

12. Miyata K, Yotsumoto F, Fukagawa S, Kiyoshima C, Ouk NS, Urushiyama D, et al. Serum heparin-binding epidermal growth factor-like growth factor (HB-EGF) as a biomarker for primary ovarian cancer. Anticancer Res 2017;37:3955–60.10.21873/anticanres.11779Suche in Google Scholar

13. Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, et al. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Target Oncol 2014;9:205–14.10.1007/s11523-013-0284-7Suche in Google Scholar PubMed

14. Ma BB, Chan SL, Ho WM, Lau W, Mo F, Hui EP, et al. Intermittent versus continuous erlotinib with concomitant modified “XELOX” (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. Cancer 2013;119:4145–53.10.1002/cncr.28327Suche in Google Scholar PubMed

15. Hatch AJ, Sibley AB, Starr MD, Brady JC, Jiang C, Jia J, et al. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Cancer Med 2016;5:2249–60.10.1002/cam4.806Suche in Google Scholar PubMed PubMed Central

16. Kjaer IM, Bechmann T, Brandslund I, Madsen JS. Prognostic and predictive value of EGFR and EGFR-ligands in blood of breast cancer patients: a systematic review. Clin Chem Lab Med 2018;56:688–701.10.1158/1557-3125.ADVBC17-B63Suche in Google Scholar

17. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, GlasziouPP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Clin Chem 2015;61:1446–52.10.1373/clinchem.2015.246280Suche in Google Scholar PubMed

18. Berrahmoune H, Lamont JV, Herbeth B, FitzGerald PS, Visvikis-Siest S. Biological determinants of and reference values for plasma interleukin-8, monocyte chemoattractant protein-1, epidermal growth factor, and vascular endothelial growth factor: results from the STANISLAS cohort. Clin Chem 2006;52:504–10.10.1373/clinchem.2005.055798Suche in Google Scholar PubMed

19. Svoboda T, Wagner A, Speiser P, Clodi M, Luger A. Epidermal growth factor plasma concentrations in healthy control persons, acute and chronic stress and during pregnancy. Horm Metab Res 1992;24:582–4.10.1055/s-2007-1003395Suche in Google Scholar PubMed

20. Peterson EA, Shabbeer S, Kenny PA. Normal range of serum Amphiregulin in healthy adult human females. Clin Biochem 2012;45:460–3.10.1016/j.clinbiochem.2011.12.029Suche in Google Scholar PubMed

21. Lemos-Gonzalez Y, Rodriguez-Berrocal FJ, Cordero OJ, Gomez C, Paez de la Cadena M. Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma. Br J Cancer 2007;96:1569–78.10.1038/sj.bjc.6603770Suche in Google Scholar PubMed PubMed Central

22. Baron AT, Lafky JM, Suman VJ, Hillman DW, Buenafe MC, Boardman CH, et al. A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. Cancer Epidemiol Biomark Prev 2001;10:1175–85.Suche in Google Scholar

23. Petersen ER, Nielsen AA, Christensen H, Hansen T, Pedersen O, Christensen CK, et al. Vejle Diabetes Biobank – a resource for studies of the etiologies of diabetes and its comorbidities. Clin Epidemiol 2016;8:393–413.10.2147/CLEP.S113419Suche in Google Scholar PubMed PubMed Central

24. El-Hayek S, Demeestere I, Clarke HJ. Follicle-stimulating hormone regulates expression and activity of epidermal growth factor receptor in the murine ovarian follicle. Proc Natl Acad Sci USA 2014;111:16778–83.10.1073/pnas.1414648111Suche in Google Scholar PubMed PubMed Central

25. Clinical and Laboratory Standards Institute. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline – Third Edition. Wayne, PA, USA: Clinical and Laboratory Standards Institute, 2010.Suche in Google Scholar

26. Wilson DH, Rissin DM, Kan CW, Fournier DR, Piech T, Campbell TG, et al. The Simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing. J Lab Autom 2016;21:533–47.10.1177/2211068215589580Suche in Google Scholar PubMed

27. Olsen DA, Kjaer IM, Brandslund I. Development of a three-plex single molecule immunoassay enabling measurement of the EGFR ligands amphiregulin, betacellulin and transforming growth factor alpha simultaneously in human serum samples. J Immunol Methods 2018;459:63–9.10.1016/j.jim.2018.05.002Suche in Google Scholar PubMed

28. Dixon WJ. Processing data for ouliers. Biometrics 1953;9:74–89.10.2307/3001634Suche in Google Scholar

29. Lahti A, Hyltoft Petersen P, Boyd JC, Fraser CG, Jorgensen N. Objective criteria for partitioning Gaussian-distributed reference values into subgroups. Clin Chem 2002;48:338–52.10.1093/clinchem/48.2.338Suche in Google Scholar

30. Danckert B, Ferlay J, Engholm G, Hansen HL, Johannesen TB, Khan S, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, Version 8.2 (26.03.2019). Association of the Nordic Cancer Registries. Danish Cancer Society. Available at: http://www.ancr.nu, accessed on 29/03/2019.Suche in Google Scholar

Received: 2019-04-07
Accepted: 2019-06-17
Published Online: 2019-07-16
Published in Print: 2019-11-26

©2019 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. The re-emergence of dried blood spot sampling – are we ready?
  4. Review
  5. The role of platelets in bleeding in patients with thrombocytopenia and hematological disease
  6. Opinion Paper
  7. Exertional hematuria: definition, epidemiology, diagnostic and clinical considerations
  8. Guidelines and Recommendations from Scientific Societies
  9. A protocol for testing the stability of biochemical analytes. Technical document
  10. Genetics and Molecular Diagnostics
  11. Hereditary hyperferritinaemia-cataract syndrome (HHCS) – an underestimated condition: ferritin light chain variant spectrum in German families
  12. General Clinical Chemistry and Laboratory Medicine
  13. Performance of a web-based application measuring spot quality in dried blood spot sampling
  14. Clinical application of a dried blood spot assay for sirolimus and everolimus in transplant patients
  15. Plasma and dried blood spot lysosphingolipids for the diagnosis of different sphingolipidoses: a comparative study
  16. Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer’s disease
  17. Integrity of serum samples is changed by modified centrifugation conditions
  18. Heparin and citrate additive carryover during blood collection
  19. Copeptin – a biomarker of short-term mortality risk (7 days) in patients with end-stage liver disease
  20. Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits
  21. Measurement of α-dicarbonyl compounds in human saliva by pre-column derivatization HPLC
  22. Establishment of the intelligent verification criteria for a routine urinalysis analyzer in a multi-center study
  23. Reference Values and Biological Variations
  24. A new indirect estimation of reference intervals: truncated minimum chi-square (TMC) approach
  25. EGFR and EGFR ligands in serum in healthy women; reference intervals and age dependency
  26. Early pregnancy reference intervals; 29 serum analytes from 4 to 12 weeks’ gestation in naturally conceived and uncomplicated pregnancies resulting in live births
  27. Paediatric reference intervals for 17 Roche cobas 8000 e602 immunoassays in the CALIPER cohort of healthy children and adolescents
  28. Hematology and Coagulation
  29. Study of the analytical performance at different concentrations of hematological parameters using Spanish EQAS data
  30. Multicenter performance evaluation of the Abbott Alinity hq hematology analyzer
  31. Cardiovascular Diseases
  32. Fast 0/1-h algorithm for detection of NSTEMI: are current high-sensitivity cardiac troponin assays fit for purpose? An EQA-based evaluation
  33. Infectious Diseases
  34. Diagnostic performance of cerebrospinal fluid free light chains in Lyme neuroborreliosis – a pilot study
  35. Letters to the Editor
  36. Quality management at the national biobanking level – establishing a culture of mutual trust and support: the BBMRI.at example
  37. Molecular diagnosis of MODY3 permitted to reveal a de novo 12q24.31 deletion and to explain a complex phenotype in a young diabetic patient
  38. Increased C-reactive protein values in the absence of inflammation: monoclonal immunoglobulin interference in immunonephelometry
  39. An approach based on simulated hemolysis for establishing the hemolysis index threshold for high-sensitivity cardiac troponin T assay
  40. Utility of the icteric index for the management of bilirubin test requesting
  41. Quality control of monocyte volume and distribution width parameters of the Beckman Coulter DxH series
  42. Mozhaisk haemoglobin variant effects on leukocyte differential channel using the Sysmex XN series
  43. Detection of a novel hemoglobin variant Hb Liaoning by matrix assisted laser desorption/ionization-time of flight mass spectrometry
  44. Appropriateness of repetitive therapeutic drug monitoring and laboratory turnaround time
  45. Congress Abstracts
  46. 51th National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC – Laboratory Medicine)
Heruntergeladen am 9.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2019-0376/html
Button zum nach oben scrollen